60 Degrees Pharmaceuticals (SXTP) enacts 1-for-4 reverse stock split in 2026

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. approved a reverse stock split of its common stock at a final ratio of one-for-four. The company’s stockholders approved the amendment to its Certificate of Incorporation on October 8, 2025, after a recommendation from the board of directors. The company then filed a Certificate of Amendment in Delaware on January 14, 2026, which becomes effective at 12:01 a.m. Eastern Time on January 20, 2026.

At the effective time, every four shares of issued and outstanding common stock are automatically combined and converted into one share. The company is not issuing fractional shares; any fractional amounts are rounded up to one whole share. The company also issued a press release about the reverse split on January 15, 2026, which is included as an exhibit.

Insights

Equity structure and corporate actions analyst

60 Degrees Pharmaceuticals implements a 1-for-4 reverse stock split.

60 Degrees Pharmaceuticals, Inc. is consolidating its common stock through a 1-for-4 reverse stock split. Stockholders approved the amendment to the Certificate of Incorporation on October 8, 2025, and the board set the final ratio at one-for-four. The Certificate of Amendment was filed in Delaware on January 14, 2026 and becomes effective just after midnight on January 20, 2026.

Mechanically, each four shares of issued and outstanding common stock are combined into one share at the effective time, reducing the share count while increasing the per-share price mechanically. No fractional shares will exist; any fractional holdings are rounded up to one whole share, which slightly increases the resulting share count compared with pure mathematical division.

The company also issued a press release on January 15, 2026 describing the reverse stock split, and the filing includes both the Certificate of Amendment and the press release as exhibits. The overall economic effect for each stockholder depends on their pre-split holdings and the rounding up for fractional positions, while the aggregate market value will continue to be determined by trading after the effective date.

false --12-31 0001946563 DC 0001946563 2026-01-14 2026-01-14 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2026-01-14 2026-01-14 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2026-01-14 2026-01-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 14, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SXTP		The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock		SXTPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On October 8, 2025, the stockholders of 60 Degrees Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”).

The Board approved the Reverse Stock Split at a final ratio of one-for-four (1:4). On January 14, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which became effective at 12:01 a.m. Eastern Time on January 20, 2026.

At the Effective Time, each four shares of the Company’s issued and outstanding common stock were automatically combined and converted into one share of common stock. No fractional shares were issued in connection with the Reverse Stock Split and fractional amounts were rounded up to one whole share.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01. Other Events.

On January 15, 2026, the Company issued a press release with respect to the Reverse Stock Split described herein. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information furnished in this Item 8.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

Exhibit Number		Description
3.1		Certificate of Amendment to Certificate of Incorporation filed on January 14, 2026
99.1		Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of January 15, 2026
104		Cover page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.
Date: January 21, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

2